CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Appraise published research findings and current guideline recommendations on optimal management approaches to biochemical recurrence after local treatment for prostate cancer, and counsel patients regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
  • Explore available data with the use of treatment intensification using cytotoxic or secondary hormonal therapy for metastatic hormone-sensitive prostate cancer, and effectively integrate these approaches into current clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biologic factors.
  • Assess the available and emerging research database supporting the use of PARP inhibitors for patients with mCRPC, and discern how to optimally incorporate these agents into current and future treatment plans.
  • Appreciate available Phase III data documenting the efficacy of PSMA-targeted radioligand therapy in patients with progressive PSMA-positive mCRPC, and consider the potential future clinical role of this strategy.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AUA22Prostate/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY & MODERATOR — The following faculty reported relevant financial relationships with ineligible entities:
  
  FACULTY
  
  Raoul S Concepcion, MD
  Chief Science Officer
  US Urology Partners
  Nashville, Tennessee
  
  No relevant conflicts of interest to disclose.
  
  Fred Saad, MD
  Professor and Chief of Urology
  Director of GU Oncology
  Raymond Garneau Chair in Prostate Cancer
  University of Montreal Hospital Center (CHUM)
  Director, Prostate Cancer Research
  Montreal Cancer Institute/CRCHUM
  Montréal, Québec, Canada
  
  Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme.
  
  Matthew R Smith, MD, PhD
  Claire and John Bertucci Endowed Chair in Genitourinary Cancers
  Professor of Medicine
  Harvard Medical School
  Director, Genitourinary Malignancies Program
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  Advisory Committee, Consulting Agreements and Contracted Research: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc.
  
  MODERATOR
  
  Emmanuel S Antonarakis, MD
  Clark Endowed Professor of Medicine
  Division of Hematology, Oncology and Transplantation
  University of Minnesota
  Minneapolis, Minnesota
  
  Advisory Committee: AIkido Pharma Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Curium Pharma, Exact Sciences, Foundation Medicine, Invitae, Ismar Healthcare NV, Merck, Orion Corporation, Tempus; Consulting Agreements: EcoR1 Capital LLC, KeyQuest Health; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Clovis Oncology; Other: QIAGEN: licenser of technology.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, and Pfizer Inc.
  
  Release date: May 2022
  Expiration date: May 2023
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.